Tiziana Life Sciences (TLSA) Payables (2017 - 2025)

Tiziana Life Sciences (TLSA) has reported Payables for 9 consecutive years, with $7.2 million the latest figure, recorded in Q4 2025.

• Quarterly Payables fell 0.79% year-over-year to $7.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.2 million (down 0.79% YoY) and the FY2025 annual result came in at $7.2 million, down 0.79% from the prior year.
• Payables held at $7.2 million in Q4 2025 per TLSA's latest filing, from $7.2 million in the prior quarter.
• Over the last five years, Payables for TLSA reached as high as $8.9 million in Q2 2024 and fell as low as $3.8 million in Q2 2023.
• A 5-year average of $6.6 million and a median of $6.8 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables slumped 40.47% — and 2024, when it soared 137.04%.
• Year by year, Payables stood at $6.2 million in 2021, then dropped by 19.72% to $5.0 million in 2022, then grew by 28.72% to $6.4 million in 2023, then increased by 13.2% to $7.2 million in 2024, then slipped by 0.79% to $7.2 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $7.2 million, $7.2 million, and $7.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.